Read Alfred's story of joining the STAMPEDE clinical trial. His is one of the many stories featured in our 2016/17 Annual Review.
Targeted treatment up front improves survival for advanced prostate cancer, and we predict a change in thinking for precision cancer medicine.
Scientists have developed a blood test that could help doctors select the best treatment for men with aggressive prostate cancer.
We take a look at results from the STAMPEDE clinical trial, which is researching how to improve treatment for men with prostate cancer.
Offering abiraterone (Zytiga) up-front with standard hormone treatment extends survival in men whose prostate cancer has spread.
Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent.
A blood test could help predict which advanced prostate cancer patients are likely to do best when treated with certain targeted treatments.
Men with a high risk of prostate cancer recurrence could live longer if hormone treatment is given alongside radiotherapy after surgery.
Using an MRI scan to help diagnose prostate cancer could spare some men from unnecessary invasive biopsies, according to a new study.
Meet our new leaders, who are spearheading research to tackle some of the biggest questions we need to answer to help more people survive cancer.